EOS Imaging Expands Europe Market Presence With First Installation In Belgium

Largest Hospital in Belgium Becomes First to Adopt Low Dose 2D/3D Imaging

PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the Pellenberg campus of the University Hospitals Leuven network is the first hospital in Belgium to install the EOS system.

“We are very proud to have been selected by the Pellenberg Hospital, a widely recognized and respected center for orthopedic care and innovation. Adoption of low dose 2D/3D imaging has been consistently strong in Europe, and this new installation will continue to strengthen our European market presence.”

The University Hospitals Leuven consist of five separate hospitals totaling 1,995 beds to form the largest hospital network in the country, and one of the largest networks in Europe. The Pellenberg campus, known for orthopedics, is an ESSKA (European Society for Sports, Traumatology, Knee Surgery and Arthroscopy) accredited Teaching Centre, and is the first University Hospitals Leuven campus to acquire the EOS imaging system. A second EOS system will be installed later in 2015 in the University Hospitals Gasthuisberg campus, making the Leuven network the second European hospital network after Assistance Publique - Hôpitaux de Paris, to acquire multiple EOS imaging systems.

“The Pellenberg campus at Leuven University Hospitals is a leading institution in innovative orthopedic care,” said Prof. Guy Molenaers, Chief Surgeon, Department of Orthopedic Surgery, Leuven University Hospitals. “The acquisition of the EOS imaging system for our orthopedic patients is another example of our commitment to securing the most efficient, effective and safest treatment options for our patients.”

Marie Meynadier, CEO of EOS imaging, said, “We are very proud to have been selected by the Pellenberg Hospital, a widely recognized and respected center for orthopedic care and innovation. Adoption of low dose 2D/3D imaging has been consistently strong in Europe, and this new installation will continue to strengthen our European market presence.”

The EOS^® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: annual results for 2014 and turnover for the 1st quarter of 2015: on April 20, 2015 (after market).

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

Help employers find you! Check out all the jobs and post your resume.